Clinical Trial

Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The study titled \"Transnasal sphenopalatine ganglion block for treatment of acute subarachnoid hemorrhage associated headache\" is a randomized controlled pilot study aimed at evaluating the efficacy of a transnasal sphenopalatine ganglion (SPG) block in addition to standard pain medication for reducing headache severity in patients with acute subarachnoid hemorrhage (aSAH). The study also examines whether this intervention can reduce opioid requirements during hospitalization and upon discharge.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-09-27; most recent amendment 2025-11-24.
Status change: Not Yet Recruiting → Recruiting 2024-10-21
Trial Details
NCT Number NCT06621329
Lead Sponsor University of California, Davis
Collaborators: Agnes Marshall Walker Foundation
Conditions SAH (Subarachnoid Hemorrhage), Headache
Enrollment 40 participants
Start Date 2024-10-17
Primary Completion 2026-07 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-11-26